Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2020

Open Access 01-12-2020 | Cough | Letter to the Editor

Laryngopharyngeal reflux in chronic obstructive pulmonary disease - a multi-centre study

Authors: Julia Sanchez, Desiree M. Schumann, Meropi Karakioulaki, Eleni Papakonstantinou, Frank Rassouli, Matthias Frasnelli, Martin Brutsche, Michael Tamm, Daiana Stolz

Published in: Respiratory Research | Issue 1/2020

Login to get access

Abstract

Reflux of gastric content has been associated with recurrent exacerbations of chronic obstructive pulmonary disease (COPD). We aimed to assess the prevalence of laryngopharyngeal reflux (LPR) in COPD and if LPR is a contributing factor to clinically relevant outcomes in COPD. We evaluated a total of 193 COPD patients (GOLD I-IV) with a 24-h laryngo-pharyngeal pΗ-monitor. LPR was observed in 65.8% of COPD patients and it was not significantly associated with clinically relevant outcomes of COPD. Treatment with PPI significantly decreased the upright RYAN score (p = 0.047) without improving lung function. Furthermore, the presence or severity of LPR cannot be diagnosed based solely on symptoms and questionnaires.
Appendix
Available only for authorised users
Literature
1.
2.
Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165–85.CrossRef
3.
Celli BR, MacNee W. ATS/ERS task force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–46.CrossRef
4.
Clini EM, Boschetto P, Lainscak M, Janssens W. Comorbidities in chronic obstructive pulmonary disease from assessment to treatment. Biomed Res Int. 2014;2014:414928.
5.
Nussbaumer-Ochsner Y, Rabe KF. Systemic manifestations of COPD. Chest. 2011;139(1):165–73.CrossRef
6.
Pratter MR. Overview of common causes of chronic cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1 Suppl):59S–62S.CrossRef
7.
Baumeler L, Papakonstantinou E, Milenkovic B, Lacoma A, Louis R, Aerts JG, et al. Therapy with proton-pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD. Respirology. 2016;21(5):883–90.CrossRef
8.
Sakae TM, Pizzichini MM, Teixeira PJ, Silva RM, Trevisol DJ, EP. Exacerbations of COPD and symptoms of gastroesophageal reflux: a systematic review and meta-analysis. J Bras Pneumol. 2013;39(3):259–71.CrossRef
9.
Rascon-Aguilar IE, Pamer M, Wludyka P, Cury J, Coultas D, Lambiase LR, et al. Role of gastroesophageal reflux symptoms in exacerbations in COPD. Chest. 2006;130(4):1096–101.CrossRef
10.
Lin YH, Tsai CL, Chien LN, Chiou HY, Jeng C. Newly diagnosed gastroesophageal reflux disease increased the risk of acute exacerbation of chronic obstructive pulmonary disease during the first year following diagnosis - a nationwide population-based cohort study. Int J Clin Pract. 2015;69(3):350–7.CrossRef
11.
Casanova C., Baudet JS., del VAlle Velasco M., Martin JM., Aguirre-Jaime A., de Torres JP., et al. Increased gastro-oesophageal reflux disease in patients with severe COPD. Eur Respir J 2004;23(6):841–845.
12.
Iliaz S, Iliaz R, Onur ST, Arici S, Akyuz U, Karaca C, et al. Does gastroesophageal reflux increase chronic obstructive pulmonary disease exacerbations? Respir Med. 2006;115:20–5.CrossRef
13.
Hamdan AL, Ziade G, Turfe Z, Beydoun N, Sarieddine D, Kanj N. Laryngopharyngeal symptoms in patients with chronic obstructive pulmonary disease. Eur Arch Otorhinolaryngol. 2016;273:953–8.CrossRef
14.
Oelschlager BK, Chang L, Pope CE 2nd., Pellegrini CA. Typical GERD Symptoms and esophageal pH monitoring are not enough to diagnose pharyngeal reflux. J Surg Res. 2005;128(1):55–60.CrossRef
15.
Hamdan AL, Jaffal H, Btaiche R, Turfe ZA, Bawab I, Kanj N, et al. Laryngopharyngeal symptoms in patients with asthma: a cross-sectional controlled study. Clin Respir J. 2016;10:40–7.CrossRef
16.
Ylitalo R, Thibeault SL. Relationship between time of exposure of laryngopharyngeal reflux and gene expression in laryngeal fibroblasts. Ann Otol Rhinol Laryngol. 2006;115(10):775–83.CrossRef
17.
Jung YH, Lee DY, Kim DW, Park SS, Heo EY, Chung HS, et al. Clinical significance of laryngopharyngeal reflux in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:1343–51.PubMedPubMedCentral
18.
Eryuksel E, Dogan M, Olgun S, Kocak I, Celikel T. Incidence and treatment results of laryngopharyngeal reflux in chronic obstructive pulmonary disease. Eur Arch Otorhinolaryngol. 2009;266(8):1267–71.CrossRef
19.
Benson VS, Mullerova H, Vestbo J, Wedzicha JA, Patel A, Hurst JR, et al. Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease. Respir Med. 2015;109(9):1147–54.CrossRef
20.
Ayazi S, Lipham JC, Hagen JA, Tang AL, Zehetner J, Leers JM, et al. A new technique for measurement of pharyngeal pH: normal values and discriminating pH threshold. J Gastrointest Surg. 2009;13(8):1422–9.CrossRef
21.
Stolz D, Papakonstantinou E, Grize L, Schilter D, Strobel W, Louis R, et al. Time-course of upper respiratory tract viral infection and COPD exacerbation. Eur Respir J. 2019;54(4):1900407.
22.
Stolz D, Hirsch HH, Schilter D, Louis R, Rakic J, Boeck L, et al. Intensified therapy with inhaled corticosteroids and long-acting β(2)-agonists at the onset of upper respiratory tract infection to Prevent chronic obstructive pulmonary disease exacerbations. A multicenter, randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2018;197(9):1136–46.CrossRef
23.
Kilic M, Ozturk F, Kirmemis O, Atmaca S, Guner SN, Caltepe G, et al. Impact of laryngopharyngeal and gastroesophageal reflux on asthma control in children. Int J Pediatr Otorhinolaryngol. 2013;77(3):341–5.CrossRef
24.
Wang G, Qu C, Wang L, Liu H, Han H, Xu B, et al. Utility of 24-hour pharyngeal pH monitoring and clinical feature in laryngopharyngeal reflux disease. Acta Otolaryngol. 2019;139(3):299–303.CrossRef
25.
Broers C, Tack J, Pauwels A. Review article: gastro-oesophageal reflux disease in asthma and chronic obstructive pulmonary disease. Aliment Pharmacol Ther. 2018;47(2):176–91.CrossRef
26.
Morice AH, Millqvist E, Bieksiene K, Birring SS, Dicpinigaitis P, Domingo Ribas C, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. 2020;55(1):1901136.
Metadata
Title
Laryngopharyngeal reflux in chronic obstructive pulmonary disease - a multi-centre study
Authors
Julia Sanchez
Desiree M. Schumann
Meropi Karakioulaki
Eleni Papakonstantinou
Frank Rassouli
Matthias Frasnelli
Martin Brutsche
Michael Tamm
Daiana Stolz
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2020
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-020-01473-2

Other articles of this Issue 1/2020

Respiratory Research 1/2020 Go to the issue

Research

Predictors of fatality including radiographic findings in adults with COVID-19

Research

Performance of brief ICF-sleep disorders and obesity core set in obstructive sleep apnea patients

Research

Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis

Research

FluA-p score: a novel prediction rule for mortality in influenza A-related pneumonia patients

Research

Influenza A virus enhances ciliary activity and mucociliary clearance via TLR3 in airway epithelium

Research

Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits